Leading clinicians in the U.K. have set out a blueprint for integrating pharmacogenomic testing into prescribing in all cases where there is a known association between a gene variant and how an individual will respond – or not – to a particular drug.
The challenging financial environment of 2022 will lead to an increase in partnerships, according to representatives of the two big Swiss biopharma companies, Roche Holding AG and Novartis AG.
LONDON – A U.K. trial has shown it is possible to seamlessly insert point-of-care genotype testing for a rare genetic variant that causes hearing loss into the current care pathway in neonatal treatment for sepsis.
Janssen Pharmaceutical Cos, Inc.’s CAR T-cell therapy, Carvykti (ciltacabtagene autoleucel), looks set for approval in Europe after endorsement by regulators for advanced multiple myeloma. At its monthly meeting, the EMA’s Committee for Medicinal Products for Human Use recommended Carvykti for adults with relapsed and refractory disease who have received at least three prior therapies and whose cancer has worsened since their last treatment.
Astrazeneca plc is selling its disease management platform Amaze to U.K. digital therapeutics company Huma Therapeutics Ltd. through a new collaboration agreement. The companies said they will work together to launch Software as a Medical Device (SaMD) companion apps for several therapeutic areas and accelerate adoption of decentralized clinical trials (DCTs). The partnership marks Astrazeneca’s first major deal in the digital health space.
Building on its partnership with the World Health Organization (WHO) to improve access in Sub-Saharan Africa to vaccines, drugs and medical technologies, the EU committed at least €24.5 million (nearly US$27 million) to fund projects aimed at tackling some of the barriers to that access.
While the focus of much U.K. Chancellor Rishi Sunak’s spring statement 2022 was on the rising cost of living, there was welcome relief for life sciences and research-based industries as part of a drive to restore economic growth.
As it settles a patent dispute with Japan’s Chugai Pharmaceutical Co. for $775 million, the U.K.’s Astrazeneca plc is looking to bring intellectual property in-house by snapping up a new generation of talented scientists.
With the World Health Organization’s COVAX facility having more COVID-19 vaccine doses available than have been requested by the countries it was designed to help, industry groups are pushing back against the proposed TRIPS waiver for COVID-19 vaccines.
Headlines the world over have been dominated by the resilience of the Ukrainian military – but the country’s clinical research body said that amid the chaos of war, trials are carrying on despite the destruction of hospitals and civilian infrastructure. As revealed by BioWorld, big pharma sponsors are putting clinical studies on hold in Russia, Ukraine and Belarus as the war plays havoc with medical supplies and the normal functioning of society.
RSS
